What a strong submission includes: your baseline BMI before starting any treatment (not your current weight if medication has already helped, since insurers will use a lower number against you), a full accounting of comorbidities, prior weight loss interventions, relevant lab work, and a clear clinical rationale for why Wegovy specifically is the appropriate treatment
for context, see SingleCare, approximately 1% of patients taking Ozempic reported experiencing heart palpitations, which frames palpitations as rare but clinically relevant
Professor Foltynie added: It is not yet clear whether there may be a subgroup of people with Parkinsons disease who may get benefit from the use of exenatide
This acid-base disturbance often accompanies hypokalemia and hypochloremia (low chloride)
Start Low and Go Slow: Most providers will start you on a very low dose of Wegovy and gradually increase it over several months
A decision on the preemption issue could potentially be reached by the end of the year